Skip to main content
Arbor Rapha Capital BioHoldings Corp IPortfolioRapha Capital Management

SPACtacular spooky season for Arbor Rapha’s blank check; a $180M Entrada onto Wall Street

By October 29, 2021November 2nd, 2021No Comments

By Kyle LaHucik | Oct 29, 2021 10:15am | FierceBiotech

Add Entrada Therapeutics to the list of preclinical biotechs that think they can convince investors their drugs will work in humans as it raises $181.5 million on the Nasdaq Friday.

There is a clinical-stage biotech joining the Wall Street frenzy before the weekend, though. Aura Biosciences seeks $75.6 million from its own IPO. The oncology biotech presented interim mid-stage safety data on its lead program in a certain melanoma earlier this month.

Oh, and don’t forget that spooky SPAC season is back as Arbor Rapha Capital Bioholdings, a blank-check company, lands on the public markets today to raise $150 million for a future biopharma merger.

For its part, Entrada is joining the public markets at an upsized price of $20 a share seven months after inking a $116 million series B to ramp up clinical development of a pipeline of investigational treatments for rare diseases. The biotech’s goal is to get biologics through cell membranes so they can hit targets within the cell, where many disease targets are found but are largely inaccessible.

First up are two assets for the neuromuscular disease Duchenne muscular dystrophy, then two other oligonucleotides for myotonic dystrophy Type 1 and Pompe disease. Undisclosed neurodegenerative and inflammatory diseases are also targets.

Arbor Rapha Capital Bioholdings, on the other hand, is looking to raise cash from its IPO to buy a biopharma using the blank-check model. The biotech investment manager, Rapha Capital Management, which is behind the SPAC, Arbor Rapha, has invested in the likes of Takeda-partnered, Poseida Therapeutics, Bellicum Pharmaceuticals and NexImmune.

Rapha Capital Management launched a $100 million series A fund for life sciences startups in April

To view original content click:

Rapha Capital Management, LLC is providing this website for informational purposes only. Nothing on this website is intended to constitute, or should be deemed to be, financial advisory, legal, tax, accounting or other professional advice to you or any other party; be an opinion of the appropriateness or suitability of any investment; or constitute an offer to sell or solicitation of an offer to buy any security or investment. This website and its content (collectively, “Content”) is intended for general informational purposes only and should not be acted upon without first obtaining financial advisory, legal, tax, accounting or other professional advice from your consultant or other professional with respect to your own personal investment objectives, financial circumstances and needs. Nothing on the Site shall be considered a recommendation or solicitation to buy or an offer to sell a security to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the securities laws of such jurisdiction. Any investment decisions you may make on the basis of any information found on this web site is your sole responsibility. Prior to making any investment or hiring any investment manager you should consult with a professional financial advisor, legal and tax advisor to assist in due diligence as may be appropriate and determining the appropriateness of the risk associated with a particular investment. In no event shall Rapha Capital Management, LLC be responsible or liable for the correctness of any such material or for any damage or lost opportunities resulting from use of these data.